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Abstract
Bright/ARID3A is a nuclear matrix-associated transcription factor that stimulates immunoglobulin
heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. Bright positively
activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix
attachment regions (MARs) flanking the IgH intronic enhancer (Eμ). Over-expression of Bright in
cultured B cells was shown to correlate with DNase hypersensitivity of Eμ. We report here further
efforts to analyze Bright-mediated Eμ enhancer activation within the physiological constraints of
chromatin. A system was established in which VH promoter-driven in vitro transcription on
chromatin- reconstituted templates was responsive to Eμ. Bright assisted in blocking the general
repression caused by nucleosome assembly but was incapable of stimulating transcription from
prebound nucleosome arrays. In vitro transcriptional derepression by Bright was enhanced on
templates in which Eμ is flanked by MARs and was inhibited by competition with high affinity Bright
binding (P2) sites. DNase hypersensitivity of chromatin-reconstituted Eμ was increased when
prepackaged with B cell nuclear extract supplemented with Bright. These results identify Bright as
a contributor to accessibility of the IgH enhancer.
Background
Numerous studies have demonstrated the requirement of
the intronic enhancer (Eμ) in transcription of immu-
noglobulin heavy chains (reviewed in [1]). In vivo, Eμ is
required for successful B-cell development, and in its
absence, completion of antigen receptor assembly
through VDJ recombination is blocked [2,3]. Based on
chromatin immunoprecipitation (ChIP) measurements
of its histone modification status, Eμ assumes an accessi-
ble chromatin configuration specifically in B cells [4-6].
Conventional transcription factors may seize upon this B
cell-accessible state to bind to Eμ for transactivation via
VDJ-associated promoters (Fig. 1A). Transcriptional acti-
vators further exploit increasingly accessible chromatin
structures to enhance their binding as B cells progress
through development [7].
The Eμ core is flanked on both sides by nuclear matrix
associating regions (MARs) (Fig. 1A,B) [8]. As proposed
for MARs in general, the Eμ MARs are thought to anchor
higher order chromatin into discrete looped domains and
to attach them to the nuclear matrix – a site where pro-
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teins essential for transcription might reside [9]. While the
importance of the Eμ core is universally accepted, the role
of their associated MARs remains controversial. The Eμ
MARs were initially implicated in locus down-regulation
[10-12], an argument strengthened by the observation
that the enhancer core alone will activate gene expression
in non-B cells [12]. Conversely, the Eμ MARs have been
shown to stimulate IgH transcription in B cells (reviewed
in [13]), perhaps by impacting chromatin structure of the
enhancer [14-17]. For example, targeted in vivo deletion of
both intronic MARs reduced IgH transcription 5–10 fold
[17]. However, deletion of the endogenous MARs in a
hybridoma cell line had modest effects, implying a redun-
dant function for the MARs and the core enhancer in
maintaining IgH expression [18]. Studies which examined
the Eμ MARs in VDJ rearrangement have had variable out-
comes, largely depending on the method used to delete
the MARs and whether the endogenous locus or a trans-
genic locus was examined [3,18-20]. A requirement for
MAR function in vivo but not in cell lines was most con-
vincingly demonstrated by the finding that the Eμ MARs
were necessary for generating long-range chromatin acces-
sibility in ectopically integrated reporter gene constructs
in transgenic mice [16,17].
Bright, a nuclear matrix-associated, B cell-restricted regu-
lator of IgHtranscription, binds with differential affinity
to four ATC-rich motifs (P1–P4, Fig. 1B) within the Eμ
MARs to activate transcription of IgH [21]. Bright is stage-
specifically expressed in B lymphocytes, where it accumu-
lates primarily within the cytoplasm and the nuclear
matrix [22-24]. In addition to its participation in IgH tran-
scription, a function for Bright in cell cycle regulation was
suggested by the finding that a fraction of nuclear matrix-
associated Bright fractionated into PML nuclear bodies
[25]. Consistent with this notion, ectopic over-expression
of Bright in embryonic fibroblasts leads to their immortal-
ization via accumulation of Cyclin E and activation of
E2F1 [26]. Potential relevance of these observations to B-
cell malignancy is suggested by the finding that the sub-
type of diffuse large B-cell lymphoma with the worst clin-
ical prognosis has elevated levels of Bright [27,28].
Bright is the founder of the 13-member (in humans)
ARID (AT-Rich Interaction Domain) family [29]. Bright/
ARID3A and several other ARID members (or their fly or
yeast orthologues) have been implicated directly or indi-
rectly in chromatin remodeling [30-35]. As often seen
with remodeling proteins, Bright has strict contextual
requirements for transactivation [21,30]. For example,
Bright cannot transactivate via out-of-context, concate-
nated P binding sites, and transactivation is maximal on
integrated substrates [21,30]. Bright binding to its highest
affinity P2 site within the Eμ 5' MAR induces severe (80–
90)° bending [21,30]. Over-expression of Bright in a
mature B cell line induced DNAse I hypersensitivity
extending through both Eμ MARs [30]. These results sug-
gest that the enhancer assumes a more open chromatin
configuration as a direct or indirect consequence of
Bright.
To address the issue directly, we have examined Bright
transcriptional activation in an Eμ-responsive chromatin-
reconstituted in vitro system. Our results support a role for
Bright, or a Bright complex which retains Eμ MAR bind-
ing, in chromatin remodeling of the enhancer.
Results
Rationale and reaction order
In vitro transcription on reassembled chromatin templates
is the only in vitro system in which transcriptional
enhancement over distances of 1–2 kb has been achieved
(e.g., [36]). Activity requires that the template be pack-
aged into chromatin and that the transcriptional regula-
tory factors be present before or during chromatin
formation so that general repression caused by nucleo-
some assembly will be blocked.
The 3 template DNAs employed in this study are shown in
Fig. 1C, and their construction is detailed in Methods and
Materials. Transcription is driven from the promoter of
the rearranged VDJ expressed by the BCL1 leukemia B cell
line [37]. VHBCL1 extends ~270 bp upstream of the 5'
most transcriptional initiation site and includes the con-
served heptamer and octamer binding motifs [38] (Fig.
1D). VHBCL1 has been shown to have strong in vitro activ-
ity when assayed in nuclear extracts [39,40]. The Eμ core
alone (Eμ) or flanked by 5' and 3' MARs (Eμ+MARs) is
positioned ~2 kb downstream (or ~400 bp upstream on
the circular plasmid backbone) (Fig. 1C).
Our experimental design is shown in Fig. 1E. There are
two orders of addition. In the first, naked DNA templates
are prebound with nuclear extract from B-cell lines, or
with recombinant Bright, or with B-cell extracts supple-
mented with recombinant Bright (or with buffer) (Step 1).
Chromatin is assembled using S-190 extracts from 4 hr
Drosophlia  embryos supplemented with core histones
[41,42]. Following chromatin assembly (Step 2), pack-
aged templates are assayed upon addition of nucleotide
triphosphates for transcription initiated off of the VHBCL1
promoter by quantitative RNase protection. Chromatin
alterations are measured by DNase I digestion and indi-
rect end labeling. In the second order of addition, extracts
or purified Bright are added following chromatin assem-
blies.
The Step 1 condition will reveal direct effects on chroma-
tin structure. In this scheme, extracts or purified Bright
prebound to the naked DNA template before or duringMolecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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chromatin formation can derepress the general transcrip-
tional repression of assembled nucleosomes. If an effect is
seen at addition of extract or Bright at step 2, this would
suggest that transcriptional activation requires binding to
a pre-formed, reconstituted nucleosome array.
Assembly of chromatin on IgH templates
Chromatin assembly on the three templates described
above was carried out as detailed in Materials and Meth-
ods. A kinetic analysis of micrococcal nuclease (MNase)
digestion of assembly on VHBCL1-Eμ+MARs is shown in
Fig. 2. Assembly was complete in ~30 min, and in the
Schematics of the immunoglobulin heavy chain (IgH) locus and of the templates and strategies used for chromatin reconstituted  in vitro transcription assays Figure 1
Schematics of the immunoglobulin heavy chain (IgH) locus and of the templates and strategies used for chro-
matin reconstituted in vitro transcription assays. (A). Eμ within the rearranged VDJ-Cμ murine (IgH) locus. Promoter, 
p; direction of transcription, rightward arrow; exons, open boxes; 5' and 3' MARs, hatched boxes; Eμ core, filled box. (B). 
Detailed schematic of the enhancer sites indicating DNA binding sites and proteins that bind to them to activate (positive fac-
tors) or to repress (negative factors) transcription (reviewed in [1]). P1–P4 denote Bright-binding ''P sites'' within the 5' and 3' 
MARs; the strong P2 site of Bright is indicated by a filled circle. Hinf1 sites (H) operationally define the core region, and XbaI 
sites (X) flank the MARs. (C). Templates for in vitro chromatin assembly/transcription. VDJ and upstream region was derived 
from the rearranged VDJ expressed by the BCL1 murine leukemia cell line (37). Templates contain VDJ with no enhancer (P-
only) or, ~2 kbp downstream, the Eμ core with (+) or without the 5' and 3' MARs. (D). Probes and protected products used 
for in vitro transcription reactions and RNAse protection assays. Transcription in vitro and in vitro is initiated from two major 
start sites (indicated by arrows), resulting in protected products (shown below) of 55 and 43 bases. (E). Order of addition and 
strategy for in vitro transcription reactions. As detailed in the text, Step 1 conditions examine transcription following addition of 
factors (extract only, recombinant Bright, or Bright-supplemented extract) or buffer alone prior to chromatin assembly upon 
templates. Step 2 conditions measure transcription when factors are added after assembly of chromatin. Transcription is initi-
ated by addition of nucleoside-triphosphates (NTPs).
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absence of an ATP regenerating system (-ATP lanes),
assembly was suppressed. Similar results were obtained
for the other templates using this assay and for all tem-
plates using a DNA supercoiling assay (data not shown).
We conclude that our nucleosomal arrays are sufficient for
in vitro transcription.
Transcription from in vitro assembled VH-promoter-driven 
templates is responsive to Eμ
Having succeeded in reconstituting regularly spaced
nucleosomes on IgH template DNA, we tested whether
the templates of Fig. 1C could direct transcription and,
importantly, whether their activities were sensitive to the
presence in cis of Eμ or Eμ+MARs. We prepared nuclear
extracts from the human Burkitt lymphoma line, BJAB,
shown previously by us [39] and others [43] to be highly
active for in vitro transcription of naked IgH templates. As
shown in Fig. 3, transcripts were correctly initiated from
all templates in the absence (N lanes) or presence (D and
R lanes) of chromatin as confirmed by their sizes relative
to authentic BCL1 transcripts (lane 2). Transcription initi-
ated from each template was repressed (R) when reconsti-
tuted with chromatin prior to addition of BJAB nuclear
extract under Step 2 conditions (R lanes 5, 8, and 11).
Importantly, transcription was derepressed (D) for all
templates by pre-binding BJAB nuclear extract (D lanes 4,
7, and 10). Equal inputs, confirmed by anti-Bright West-
ern blotting (Fig. 3, lower panel) allowed us to estimate
the quantitative effects of cis-acting sequences. Impor-
tantly, we observed Eμ enhancer-dependent stimulation
in this system under Step 1 conditions (compare D lanes
± Eμ ; lanes 4 vs 7). The inclusion of 5' and 3' MARs repro-
ducibly enhanced transcription levels achieved with Eμ
alone (compare D lanes, Eμ vs Eμ+MARs; lanes 7 vs 10).
We conclude that our chromatin reconstituted in vitro
transcription system is responsive to the enhancer and
adequate to address the central question of the role of
Bright. Furthermore, the data are consistent with the con-
clusions of Forrester et al. [16] in suggesting that Eμ MARs
positively contribute to IgH transcriptional activity
through a chromatin-based mechanism.
Choice and production of endogenous and recombinant 
Bright
We reasoned that the abundance of endogenous Bright
within a B cell nuclear extract would directly correlate
with its transcriptional activity. As shown in the Western
analysis of Fig. 4A, Bright levels varied broadly among the
human B cell lines examined. We prepared standard
nuclear extracts fractionated over heparin agarose from
the relatively Bright-low (Namalwa, lane 8) and Bright-
high (Nalm6, lane 4) cell lines.
Next, we sought to purify recombinant Bright to replace or
to complement extracts for reaction Steps 1 and 2. Several
methods to produce full-length Bright (1–601) in E. coli
were attempted, but these attempts were unsuccessful in
producing functional protein (data not shown). The
material remained insoluble and could not be actively (as
judged by EMSA; data not shown) renatured from inclu-
sion bodies. However, we produced sufficient quantities
of an N-terminally His-tagged truncation (residues 177–
601). This same truncation was previously shown to be
indistinguishable from wild-type as an Eμ transactivator
in transfected B cell lines [21]. As judged by SDS-PAGE
chromatography (Fig. 4B, left panel), Bright (177–601)
was purified to near homogeneity by a combination of
affinity and ion exchange chromatography. The faster
migrating species was confirmed by Western analysis
(data not shown) as a Bright degradation product. This
degradation was prevented/significantly reduced (Fig. 4B,
left panel, lane 5) by transformation into a chaperone
over-expressing E. coli strain [44].
Following purification, proteins were tested for DNA
binding by EMSA. The ~50 kD Bright (177–601) or its ~20
kD (d177–601) degradation product bound to the 5' Eμ
MAR-containing P2 site with specificity (Fig 4B, right
panel, lanes 5–7) but with apparent lower affinity than
endogenous Bright-containing Nalm6 extract (although it
was difficult to compare their concentrations quantita-
tively). Full-length Bright binds to MARs as a tetramer
[21], and the C-terminus-proximal REKLES domain
(retained in both full-length and 177–601 proteins) is
necessary and sufficient for tetramerization (24). Accord-
ingly, the sizes of the DNA-protein complexes were con-
sistent with multimerization of Bright (177–601). We
conclude that bacterially-expressed Bright (177–601) is
sufficient for use in in vitro transcription experiments.
Bright stimulates in vitro transcription by relieving the 
inhibitory effect of chromatin
Transcription reactions were carried out using the tem-
plates, Bright-rich and low-concentration extracts, and
recombinant Bright (177–601) protein described above.
We summarize all the data in Table 1 and key RNase pro-
tection results are presented in Fig. 5. Both nuclear
extracts, but not Bright (177–601) alone, stimulated in
vitro transcription of Eμ and of Eμ+MARs equivalently as
naked DNA templates (eg, N lanes 1,2,9,10). These activ-
ities were repressed when the factors were added in Step 2
following chromatin-reconstitution on the templates (R
lanes 3,4,11,12). Step 1 prebinding of all extracts dere-
pressed (D lanes) both templates to some extent,
although consistently stronger activity on the Eμ+MARs
template was observed for the Bright-rich Nalm6 extract
(compare lanes 13 and 15). Recombinant Bright (177–
601) alone was incapable of transactivating any of the
templates as naked DNA; nor did addition of Bright (177–
601) alone derepress chromatin assembled templatesMolecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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(data not shown; Fig. 5, lane 4; Table 1). However, its
addition at Step 1 strongly complemented the ability of
Namalwa to derepress Eμ+MARs (compare lanes 7 and 8),
while providing a more modest co-activation to Bright-
rich Nalm6 (lane 15 vs. lane 16). The data indicate a direct
role for Bright in alleviating the chromatin-mediated
repression of the enhancer.
Enhancer derepression by Bright requires P site-specific 
MAR binding
To determine if the Bright (177–601) complementation
observed in Fig. 5 required MAR binding, we titrated into
Step 1 reactions duplex oligonucleotides corresponding to
either a wild-type or mutated 5'- Eμ MAR-containing P2
Bright binding site (Fig. 6) [21,30]. Specific, dose-depend-
ent inhibition of transcription was observed for the wild-
type, but not for the mutant P2 oligo. Although there are
other interpretations, the simplest is that binding of
Bright to its MAR-containing P2 site was specifically com-
peted by excess P2 oligo.
Bright levels correlate with increased enhancer 
accessibility
DNase I hypersensitivity sites coincide with nucleosome-
free regions in chromatin. We analyzed the accessibility of
chromatin assembled in vitro on Eμ+MARs to factors
present in Namalwa nuclear extract in the absence or pres-
ence of Bright (177–601) under Step 1 conditions by
DNase digestion (Fig. 7). Preferred sites of DNase I cleav-
age were examined with respect to a downstream BglI site
by using a proximal probe (detailed in Materials and
Methods). While the effect was modest, Bright (177–
601)-complemented Namalwa extract rendered a consist-
ently increased and extended hypersensitivity across the
enhancer (compare lanes 3 among the panels). These
results suggest that the enhancer assumes a more open
chromatin configuration as a direct consequence of
Bright.
Discussion
Numerous ubiquitous and B cell-specific transcription
factors have been identified that transactivate the IgH
enhancer (Fig. 1B; reviewed in [1]). Functional analyses
underlying most characterizations have relied on tran-
sient reporter assays and have ignored to a large extent the
physiological role of chromatin. Chromatin imposes an
obligatory negative constraint upon enhancer accessibil-
ity. Thus, while conclusions derived from reporter
approaches are valid in the context of accessible regula-
tory elements, they do not address many basic mecha-
nisms of enhancer activation.
The concept of locus accessibility is at the heart of antigen
receptor VDJ and class switch recombination (reviewed in
[45]). However, few bonafide accessibility factors have
In vitro nucleosomal arrays assembled on the IgH enhancer Figure 2
In vitro nucleosomal arrays assembled on the IgH 
enhancer. The rate and extent of the chromatin reconstitu-
tion reaction (detailed in Methods and Materials) on the 
Eμ+MARs template (Fig. 1C) was monitored by formation of 
nucleosomes. Aliquots were removed at regular 2–240 min 
intervals, digested with MNase for 5 min, fractionated on a 
1.5% agarose gel, and then stained with ethidium bromide. 
Outside lanes, naked DNA; -ATP lanes, no ATP regeneration 
system.Molecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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been identified. Perhaps the best characterized Eμ accessi-
bility factor is the ETS transcription factor family member,
PU.1 [46,47]. PU.1 functions through the interaction with
another ETS protein, Ets-1, to transactivate Eμ and to stim-
ulate enhancer accessibility in cultured cells via μB site
binding (Fig. 1B) [48,49]. Importantly, PU.1 was
observed to stimulate in vitro transcription and Eμ accessi-
bility from chromatin reconstituted templates [50]. In
contrast, another essential Eμ-binding transactivator, E47,
appears to function indirectly by weak binding to accessi-
ble μE5/μE2 sites (Fig. 1B) [51,52].
We previously showed that Bright/ARID3A, when over-
expressed in cultured WEHI 231 B cells, facilitated DNase
I hypersensitivity of Eμ [30]. Four other members of the
13 member ARID family (including SWI1/p270 of SWI/
SNF) have been directly or indirectly implicated in chro-
matin remodeling [31-35]. Prompted by these observa-
tions, we established a system in which transcription from
in vitro assembled VH-promoter-driven templates was
responsive to Eμ. We found that Bright could complement
other B cell-derived factors to derepress the inhibitory
effects of chromatin assembled on the enhancer. The Eμ
flanking MARs were required for maximal Bright-medi-
ated in vitro transactivation. We demonstrated that the
DNase I hypersensitivity of chromatin assembled in vitro
on the enhancer was increased by Bright. These data indi-
cate a direct role for Bright and further support a role for
the Eμ MARs in facilitating a fully accessible chromatin
state of Eμ.
Our previous analysis [30] and unpublished MNase diges-
tion experiments on isolated B cell nuclei suggested that
Bright may function by Eμ nucleosomal disruption. The
simplest mechanism to explain this effect would require
that Bright reach the enhancer in the context of hetero-
chromatin. However, the results reported here showed
that Bright could alleviate chromatin-mediated repression
only if it was delivered prior to chromatin assembly. That
is, Bright cannot activate in vitro transcription by binding
to a preformed nucleosome array. In contrast, in vitro
assembled chromatin footprinting experiments revealed
In vitro transcription from the VHBCL1 promoter is stimulated by the IgH enhancer core alone (Eμ) or the enhancer and asso- ciated MARs (Eμ+MARs) on templates reconstituted under Step 1 conditions Figure 3
In vitro transcription from the VHBCL1 promoter is stimulated by the IgH enhancer core alone (Eμ) or the 
enhancer and associated MARs (Eμ+MARs) on templates reconstituted under Step 1 conditions. Transcription 
reactions were carried out as described in Materials and Methods on ~50 ng templates in which either the VHBCL1 promoter 
alone (P-only), or the Eμ core without (Eμ) or with its flanking MARs (Eμ+MARs), were positioned ~2 kbp 3'. Transcription 
was initiated by addition of NTPs. Upper panel: BCL1 transcripts, which initiate at two major sites in vivo, were detected as 
described in Fig. 1C by RNase protection following fractionation on denatured gels. Lane 1, ~2 μg yeast RNA; lane 2, ~2 μg 
total RNA from BCL1 leukemia cells; N, naked DNA; D, pre-binding with BJAB nuclear extract (~5 μg/reaction) prior to 
assembly of chromatin (Step 1 conditions of Fig. 1E); R, post-binding of BJAB extract following assembly of chromatin (Step 2 
conditions). Lower panel: Corresponding western blot of SDS-PAGE-fractionated reactions (~15 μg/lane) to monitor and nor-
malize Bright protein levels within input BJAB nuclear extract.
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Preparation of endogenous and recombinant Bright Figure 4
Preparation of endogenous and recombinant Bright. (A) Bright expression in human B cell lines. Crude nuclear 
extracts were prepared from the indicated B cell lines (lanes 2–9), from murine embryonic fibroblasts (MEFs) (-, lane 9) or 
from MEFs transduced with retroviral HA-Bright (+, lane 1). Approximately 15 μg/lane were fractionated on SDS-PAGE, and 
proteins were identified by western blotting with either an anti-ubc9 mAb (loading control, lower panel) or an affinity purified 
polyclonal rabbit anti-Bright antibody [21] (upper panel). (B) Purification from bacteria and analyses of Lac-inducible, His-
tagged Bright (177–601). Left panel: SDS-PAGE/silver stain assay for purification after each step. Affinity chromatography on Ni 
beads (Affinity, lane 2) was followed by DEAE biogel agarose chromatography (DEAE, lane3). DNA affinity chromatography 
employing a Sepharose-conjugated, high-affinity Bright binding P2 site trimer [66] produced high yield and purification (not 
shown). But we were incapable of preventing the protein (grown in DH5α) from degradation to ~20 kD (Affinity 2X, lane 4) 
unless the plasmid was transformed into K1309 [44], a strain over-producing chaperones groE and groF (Affinity 2X+Chap, lane 
5). Right panel: Specificity of P2 site-containing MAR binding of Bright (177–601) as judged by EMSA/competition. Lane 1, 
nuclear (N) extract prepared from BJAB B cells; lane 3, HA-Bright prepared from retrovirally transduced MEF nuclear extract; 
lanes 5 and 6, Bright (177–601) purified from E coli (protein inputs correspond to lanes 5 and 4, respectively, of left panel); 
lanes 2, 4, and 7, competition (of the corresponding protein sources (indicated by identically colored boxes at top of lanes) 
with ~150-fold molar excess of a P2 site-containing duplexed oligonucleotide [66]. The endogenous NF-μNR negative regula-
tor [12,66] which binds to the same P sites as Bright (Fig. 1B) is the slower mobility complex indicated in lane 3.
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that PU.1 is capable of binding μB in the repressive con-
text of chromatin [50]. The authors speculated that PU.1
might provide a platform for assembly of a "targesome", a
protein complex required for a fully accessible chromatin
structure [53]. Bright might participate in such a complex.
However, as with PU.1 [50], our competition experiments
indicated that Bright required an intact DNA binding site
to mediate maximal Eμ chromatin accessibility. This sug-
gests that Bright is recruited independently and perhaps
subsequently to PU.1, through direct binding to its P
site(s). Both PU.1 and Bright might function to clear out
nucleosomes otherwise positioned over critical cis-acting
regulatory elements within the Eμ core to provide accessi-
bility to conventional DNA-binding transactivators.
Regulation of chromatin structure by conventional pro-
tein-DNA interactions is generally considered to act only
proximal to the DNA binding site [54,55]. MARs might
Table 1: Summary of in vitro transcription results of Figures 4, 5 and data not shown. 
EXTRACT BRIGHT (177–601) No Eμ Eμ CORE Eμ+ MARS
NRD N R D N R D
Namalwa - +-++ +- + + + - +
Namalwa + + - + ++ - + ++ +/- +++
Nalm6 - + - + ++ - + ++ - +++
Nalm6 + + - + ++ - ++ ++ +/- ++++
-+ --- - - - - - -
Abbreviations are provided in the legend to Fig. 3. Intensity estimates of RPAs are indicated as weak to absent (-) or as increasingly significant (+ to 
++++) above the appropriate control for the particular reaction condition step.
Levels of in vitro transcription from chromatin assembled IgH enhancer templates correlate with levels of endogenous or  recombinant-complemented Bright Figure 5
Levels of in vitro transcription from chromatin assembled IgH enhancer templates correlate with levels of 
endogenous or recombinant-complemented Bright. Transcription reactions and templates utilizing the Eμ core with-
out (Eμ) or with flanking MARs (Eμ+MARs) were measured by RNase protection as described in legends to Figs. 1, 3, and 
Materials and Methods. Transcription reactions were performed on N, naked DNA; R, reconstituted chromatin (Step 2 reac-
tion order conditions); or D, prebound chromatin (Step 1 conditions). Protein sources: Upper panel (lanes 1–8): heparin agar-
ose purified nuclear extracts prepared from Namalwa (5 μg/reaction) that contain low levels of endogenous Bright (Fig. 4A, 
lane 8); Lower panel (lanes 9–16): Nalm6 nuclear extract (5 μg/reaction) containing high levels of endogenous Bright (Fig. 4A, 
lane 4). Extracts were supplemented in the indicated lanes (+) with ~20 ng of purified Bright (177–601; Fig 4B, lane 5). Shown 
are phosphoimages of transcription reactions following protein removal and fractionation on 6% acrylamide/5 M urea gels.Molecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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offer an exception to this case. Forrester et al [16,56] dem-
onstrated that the Eμ MARs were required to obtain nor-
mal transcription initiation rates and to produce extended
DNase I hypersensitivity across a VDJ-associated pro-
moter over 2 kbp away. The mechanism underlying such
distal accessibility induction is unknown, but it seems rea-
sonable to speculate that a MAR-binding accessibility fac-
tor might contribute. As mentioned in the Background
section, the contradictory evidence on Eμ MAR function
rests to a large extent on whether the endogenous locus or
a transgenic locus was investigated [3,18-20,34-36,57].
For example, studies using chimeric mice with targeted
deletion of the Eμ MARs reported that these elements were
dispensable for VDJ recombination and transcription of
the endogenous IgH locus [3]. However, while the endog-
enous and MAR-deleted alleles were expressed at similar
levels in splenic IgM+ B cells [3], the total numbers of IgM+
B cells in mice with a MAR deletion were less than half of
those observed in wild-type mice or mice with deletion of
only the Eμ core. This suggests that deletions of the MAR
elements may result in defects in B-cell development that
have yet to be fully appreciated. The requirement for MAR
function in transgenic animals, but not in cell lines or ani-
mals created from blastocyst fusions, is consistent with a
MAR function in chromatin remodeling during early
development or passage through the germline. This is
consistent with the results of Forrester et al. [16] and those
presented here.
In addition to Eμ, IgH-associated MARs often reside 5' of
VH promoters [58-60]. A MAR upstream of the S107 vari-
able region VH1 promoter was shown to contain specific
Bright-binding P sites [59]. Indeed, Webb and colleagues
have convincingly demonstrated that Bright can associate
with both Bruton's tyrosine kinase and TFII-I to activate
transcription of a S107 VH1 reporter through this proxi-
mal MAR in the absence of Eμ [61,62]. The existence of VH
and Eμ-associated MARs and the ability of Bright to form
multimeric MAR binding complexes [21] offers the possi-
bility of looping enhancers and promoters into close
proximity to stimulate transcription through nuclear
matrix attachment-mediated domain formation [23].
Whether the in vivo mechanisms underlying promoter-
proximal (VH) and promoter-distal (Eμ) MAR-mediated
transactivation by Bright are the same and can be accom-
modated by the looping model remain to be tested. In this
context, we note that Bright levels in adult mice spike dis-
tinctly in large preB and mature B cells [22]. At the latter
stage, maximal Bright expression and VH1 DNA binding
are induced by mitogens and cytokines (e.g., LPS, IL-5,
CD40L) that drive B lymphocytes into the cell cycle
[21,22]. Perhaps Bright might utilize quite different trans-
activation options and/or function through different IgH
MAR-associated binding sites under circumstances in
which accessibility of Eμ has already been established.
Finally, we suggest that Bright may contribute to chroma-
tin remodeling at loci other than IgH. Bright was shown
Competition of Bright-complemented in vitro transcription by a high affinity Bright-binding P2 site Figure 6
Competition of Bright-complemented in vitro transcription by a high affinity Bright-binding P2 site. Prior to 
NTP initiation of in vitro transcription on the Eμ+MARs template, either no oligonucleotide (lanes 1,2), or increasing concentra-
tions of a duplexed wild-type P2 oligo (lanes 5,6) or a duplexed mutant (mut) P2 oligo (substituted in 5 core positions to elim-
inate Bright binding) (lanes 7,8) were added to the reaction prior to chromatin assembly (Step 1 conditions). In vitro generated 
transcripts were measured by RNase protection and compared to total RNA isolated from BCL1 leukemia cells (~0.5 μg; lane 
9).Molecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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to rescue primary fibroblasts from natural replicative
senescence or from premature senescence induced by
oncogenic RASV12 [26]. As with several other ARID factors
[31,63], Bright binds retinoblastoma protein (Rb) (C.
Schmidt and PWT, unpublished results), leading to the
possibility that this tumour suppressor pathway is inacti-
vated during senescence rescue. This hypothesis is consist-
ent with the observation that Bright over-expression in
MEFs activates E2F1 and Cyclin E1 [26]. Dean and col-
leagues [64] have provided a chromatin-based explana-
tion for Rb/E2F transcriptional regulation which could
accommodate a contributor with the properties of Bright.
Conclusion
We established a chromatin-reconstituted, in vitro tran-
scription system which is responsive to the IgH enhancer.
Our results support the conclusion that Bright contributes
to enhancer function by increasing its accessibility
through matrix attachment site binding.
Materials and methods
Constructs, probes and oligonucleotides
The template plasmids for in vitro transcription were con-
structed by cloning the 593 bp BamH1-XbaI fragment that
spans the rearranged VDJ expressed by the BCL1 leukemia
cell line [37] into pUC19. This fragment (VHBCL1) con-
tains ~270 bp upstream of the 5' most transcriptional ini-
tiation site, including the conserved heptamer and
octamer binding motifs [38]. VHBCL1- Eμ was constructed
by inserting the Eμ enhancer core, as a 220 bp HinfI frag-
ment, ~2 kbp downstream in transcriptional sense (~400
bp upstream on circular plasmid) of VHBCL1. VHBCL1-
Eμ+MARs was constructed by inserting Eμ along with its
flanking 5' and 3'MARs as a 911 bp Xba I fragment into
the same location relative to VHBCL1. For the VHBCL1
Complementation of Namalwa with Bright enhances DNase hypersensitivity of chromatin-assembled IgH enhancer Figure 7
Complementation of Namalwa with Bright enhances DNase hypersensitivity of chromatin-assembled IgH 
enhancer. Following in vitro transcription, Eμ+MARs DNA template alone (left panel) or Eμ+MARs reconstituted under Step 
1 conditions with either Namalwa nuclear extract alone (middle panel) or Namalwa complemented with Bright (177–601; right 
panel) were digested with 0, 1.0, 2.0 or 3.0 μg/ml DNase I (lanes 1–4 in each panel). DNA was purified, cut with Bgl II and ana-
lyzed by Southern blotting following hybridization with a downstream (XbaI-EcoRI) probe as described in Materials and Meth-
ods. Middle and right autoradiographs were exposed ~2.5 times longer so as to better visualize hypersensitive fragments 
(horizontal bars).Molecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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antisense RNase protection probe, a 322 bp BamH1-NruI
fragment containing ~55 bp downstream from the major
initiation of transcription site was cloned into pGEM4 to
generate pBCL1-5'. The plasmid was linearized with HinfI
and transcribed in vitro by sp6 polymerase (Promega) to
generate a 95 b RNA probe. Oligonucleotides correspond-
ing to the + and - strands of wild-type (5'-CTTT-
TAACAATAATAAATTAAGTTTAAAATATTTTT-3') or
mutated (underlined bases changed to TAATT) P2 Bright
binding site within the Eμ 5' MAR were synthesized,
annealed, and the resulting duplex was gel purified as pre-
viously described [21].
Cells
The BCL1 murine leukemia, and human Burkitt's lym-
phomas (BJAB, Nalm6 and Namalwa) were maintained in
RPMI supplemented with 10% fetal calf serum. For pro-
tein purification, we employed either E. coli BL21 Star
(Invitrogen) or E coli K1309 [44], a strain overproducing
chaperones groE and groF kindly provided by Dr. G. Geor-
giou (UT Austin, Dept. of Chem. Engineering). Induction
of the chaperones was induced with 10 ng/ml-1 tetracy-
cline at the beginning of the incubation in LB or M9
media.
RNase protection
Labeling, purification, and denaturating gel analysis of the
pBCL1-5' riboprobe were carried out as previously
described [39]. After hybridization at 60°C overnight,
unduplexed probe was digested with 40 ug RNase A
(Sigma)/ml and 2500 U RNase T1 (BRL) for 1 hr at 37°C.
Protected RNA fragments were separated on 6% acryla-
mide gels containing 8 M urea, and autoradiography was
carried out for 24–96 hr.
Protein manipulations
Nuclear extracts were prepared by the method of Dignam
et al. [65] with minor modifications as described by John-
son et al. [39] to achieve final protein concentrations of
8–10 mg/ml.
An N-terminal 6X-histidine-tagged Bright truncation
(amino acids 177–601) was constructed as previously
described [21], cloned into the pET30a+ expression vector
(Novagen), and its expression induced with IPTG 30 min
after chaperone induction (see above). Harvested cells
were disrupted by sonication, and total cell lysates were
analyzed on 12% SDS-PAGE (prior to or as a monitor of
purification) with SilverStain (Invitrogen). Following
elimination of cell debris by centrifugation, supernatants
were purified by affinity chromatography over Ni2+-NTA
agarose SuperFlow according to the manufacturer's
instructions (Novagen and Qiagen). Further purification
was carried out by DEAE Bio-Gel agarose chromatography
as instructed by the vender (Pharmacia Fine Chemicals).
The Bright-containing fraction was subjected to DNA
affinity chromatography employing a Sepharose 6B-con-
jugated, high affinity Bright binding P2 site trimer (syn-
thesis and elution conditions as described [66]). The final
yield of purified Bright (177–601) was 8–20 μg from 2 l
of M9 or LB media, respectively.
Western analysis was performed according to Kim and
Tucker [24]. Proteins were separated by 9% SDS-PAGE
and transferred to Protran nitrocellulose membranes (Per-
kin Elmer). The membranes were incubated with anti-
Bright polyclonal [21] and then developed with goat anti-
rabbit IgG peroxidase-conjugated secondary (Amersham).
Bands were visualized with ECL Western Blotting Detec-
tion Reagents (Amersham).
Electrophoretic mobility shift assays (EMSA)
In vitro DNA binding and antibody supershift reactions
were performed as previously described [21,66]. Briefly,
either ~2 μg of nuclear extract or ~20 ng of purified Bright
(177–601) was incubated with ~80,000 cpm of 5' end-
labeled and gel-purified Bright-specific 5' Eμ MAR probe
(Fig. 1B). Samples were incubated for 20 min at room
temperature and then resolved on 4% polyacrylamide
gels.
Chromatin reconstitution and in vitro transcription
Chromatin was assembled onto circular plasmid DNA
templates using Drosophila core histones and S-190 assem-
bly extract, derived from Drosophila embryos as previously
described [41,42]. Briefly, template DNA (~500 ng), core
histones (~400 ng), S-190 (~3.0 μg), 3 mM ATP plus an
ATP regenerating system (30 mM phosphocreatine and 1
μg phosphocreatine kinase/ml) were incubated in 60 mM
KCl. To monitor assembly, aliquots (~100 ng DNA) were
removed at regular 2–240 min intervals, and then
digested with micrococcal nuclease (MNase) (0.4 units/
ml) for 5 min in a 30 mM CaCl2-containing, 10 mM
Hepes (pH 7.5) buffer supplemented as previously
described [42]. Reactions were deproteinized by protein K
digestion, extracted with phenol/chloroform, ethanol pre-
cipitated, fractionated on a 1.5% agarose gel, and then vis-
ualized by ethidium bromide staining. Optimal assembly
was achieved at ~1:.7 ratio of core histones: DNA.
In vitro transcription was carried out as described [41,42]
on ~50 ng naked or chromatin reassembled VHBCL1,
VHBCL1-Eμ or VHBCL1-Eμ+MARs templates. Transcrip-
tion was initiated by addition of 10 mM nucleoside tri-
phosphates (NTPs). Complementation experiments were
carried out by addition of B cell nuclear extracts (~5 μg/
reaction) and/or purified Bright (177–601) (~20 ng/reac-
tion). Variable orders of reaction were described in
Results.Molecular Cancer 2007, 6:23 http://www.molecular-cancer.com/content/6/1/23
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Chromatin accessibility measurements
DNase I digestion analysis of reconstituted chromatin
templates was performed as described [30]. Aliquots
(~100 ng DNA) were digested with DNase I (Worthing-
ton; 75 μg/ml) for various times at room temperature,
purified by proteinase K digestion, phenol/chloroform/
isoamyl alcohol (25:24:1) extraction and ethanol precipi-
tation. Digests were restricted with BglII, fractionated on a
1.4% agarose gel containing 40 mM Tris acetate and 1 mM
EDTA. The DNA was blotted overnight (Bio-Rad Zeta
probe), neutralized, baked under vacuo, and then prehy-
bridized for 2 hr overnight in 0.3 M NaCl, 15 mM sodium
phosphate (pH 7.0), 1.5 mM EDTA, 0.5% BLOTTO dried
milk powder, 1% SDS, and 500 μg/ml sonicated herring
testis DNA. The blot was hybridized overnight in the same
buffer to an ~300 bp XbaI-EcoRI restriction fragment
(downstream to the Eμ 3' MAR; Fig. 1B) radiolabeled to a
specific activity of ~109 cpm/μg (~2.5 × 107 cpm) with a
DNA labeling kit (Ambion). The sizes of hypersensitive
fragments were estimated from linear fit of log DNA size
vs mobility relative to DNA standards.
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